Table 1. LDLT and DDLT Recipient Characteristics.
LDLT (n = 195) | DDLT (n = 180] | P Value* | |
---|---|---|---|
| |||
Median [IQR] or n (%) | Median [IQR] or n (%) | ||
Donor Characteristics | |||
Age (years) | 37 [27-45] | 43 [26-51] | 0.01 |
Age >50 years old | 26 (13%) | 53 (29%) | <0.0001 |
Male | 104 (53%) | 100 (56%) | 0.42 |
Race/ethnicity | <0.0001 | ||
White | 164 (84%) | 109 (61%) | |
African American | 10 (5%) | 31 (17%) | |
Asian | 6 (3%) | 6 (3%) | |
Hispanic/Latino | 15 (8%) | 33 (18%) | |
Warm ischemia time (minutes) | 36 [30-45] | 40 [35-46] | 0.004 |
Cold ischemia time (minutes) | 41 [31-60] | 423 [300-560] | <0.0001 |
Recipient Characteristics | |||
Age (years) | 53 [49-57] | 54 [49-58] | 0.18 |
Male | 134 (69%) | 130 (72%) | 0.46 |
Race | 0.31 | ||
White | 170 (87%) | 147 (82%) | |
African American | 7 (4%) | 11 (6%) | |
Other | 18 (9%) | 22 (12%) | |
Pretransplant and Peritransplant | |||
BMI (kg/m2) | 26.8 [24.2-30.2] | 26.6 [23.9-30.2] | 0.62 |
HCC diagnosis | 35 (18%) | 54 (30%) | 0.006 |
Diabetes | 30 (15%) | 39 (22%) | 0.12 |
Transplant in the MELD Era | 110 (56%) | 108 (60%) | 0.48 |
Lab MELD (max 40) | 15 [12-18] | 19 [14-25] | <0.0001 |
Albumin (g/dL) | 2.8 [2.4-3.2] | 2.7 [2.4-3.2] | 0.52 |
Alkaline phosphatase (IU/L) | 124 [92-169] | 117 [84-154] | 0.27 |
ALT (IU/L) | 56 [33-89] | 46 [30-76] | 0.07 |
AST (IU/L) | 89 [64-136] | 79 [56-121] | 0.17 |
Bilirubin (mg/dL) | 2.5 [1.5-4.0] | 3.5 [1.8-6.7] | 0.0001 |
INR | 1.5 [1.3-1.7] | 1.6 [1.3-2.1] | 0.0006 |
Creatinine (mg/dL) | 0.9 [0.7-1.2] | 1.1 [0.8-1.5] | 0.0007 |
Immunosuppressive Therapy | |||
At Month 6† | |||
Tacrolimus | 92 (87%) | 61 (66%) | 0.0004 |
Steroid | 55 (52%) | 51 (55%) | 0.68 |
Cyclosporine | 8 (5%) | 21 (23%) | 0.002 |
MMF | 48 (45%) | 52 (56%) | 0.13 |
Sirolimus | 9 (8%) | 16 (17%) | 0.06 |
Ever used Sirolimus | 59 (30%) | 54 (30%) | 0.96 |
Post-Transplant‡ | |||
HCV treatment | 77 (55%) | 61 (48%) | 0.27 |
SVR | 18 (35%) | 10 (23%) | 0.58 |
Treatment of acute rejection | 71 (39%) | 64 (41%) | 0.80 |
Biliary complication | 84 (46%) | 43 (35%) | <0.0001 |
Bile leak | 42 (23%) | 17 (10%) | 0.001 |
Biliary stricture | 64 (36%) | 31 (19%) | 0.0014 |
Follow-up (years) | 4.94 [2.82-6.93] | 4.26 [2.54-6.03] | 0.05 |
Chi-square tests for proportions were used for categorical variables, Wilcoxon rank-sum tests were used for continuous variables, log-rank tests for post-transplant variables.
Data available for 106 LDLTs and 93 DDLTs.
Percentages were calculated using Kaplan-Meier estimation.
Abbreviations: MMF, mycophenolate mofetil; SVR, sustained virologic response.